AngioDynamics Inc Q2 2026 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Bill Plovanic - Canaccord Genuity - Analyst : Great. Thanks. Good morning and thanks for taking my questions. Just first, Jim, congratulations. I know 10 years is a long time, and it's a lot of work that you've accomplished and some great outcomes. So, my hats off to you and you'll definitely be missed. In terms of my questions are, I want to start with prostate. I know you're only a few days in. Just talk about the change to the Level 1 CPT code. How many insurers have really made that back-end change to reflect the coding change to prevent the automatic denials so far by your estimation? And then I noticed that the capital was a really strong quarter. I mean, disposables were good. They saw a very strong, but it seems like capital was even stronger, and I'm curious, is that a precursor to the prostate? Is -- they're buying the systems to get ready to do procedures.

Question: Bill Plovanic - Canaccord Genuity - Analyst : And then just on EBITDA, you mentioned that you know the back half would be, I think lower than the first half and just directionally, how do we think of adjusted EBITA in the third quarter? Is it going to be negative? And thanks for taking my questions.